Skip to content
HomeOur CompanyOur societal impact Global Health Equity Pioneering the next generation of treatment solutions

Pioneering the next generation of treatment solutions

We support innovation across the continuum of care, to help to develop new technologies, treatments and vaccines.

The new Ebola clinical trial that’s focused on helping halt future outbreaks

A groundbreaking partnership between countries, health organizations and companies worldwide—including Johnson & Johnson—hopes to find the most promising vaccines to help protect people from the virus.

Featured stories

Meet the Johnson & Johnson Scientist Who’s Helping to Fight Tropical Diseases in His Homeland

Two decades after leaving India, Anil Koul has returned to helm its Institute of Microbial Technology. For Dengue Awareness Month, we caught up with him to learn how he’s hoping to combat this tropical scourge and another disease that kills over a million worldwide.

Janssen Wins Prestigious International Prix Galien Award for MDR-TB Treatment

Ground breaking therapy offers hope for people with Multi-Drug Resistant Tuberculosis (MDR-TB)

How Johnson & Johnson is helping save children around the world from intestinal worm infections

For the fifth anniversary of the London Declaration, we’re sharing the steps the company has taken to fulfill its promise to fight neglected tropical diseases—including the development of a chewable form of mebendazole.

More from Johnson & Johnson

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.

“I’m a scientist dedicated to bringing eye-health innovations to the world”

Meet Xiao-Yu Song, Global Head of Research & Development for Vision at Johnson & Johnson, who leads a talented team that creates cutting-edge products addressing vision problems through all stages of life.

What is IL-23?

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.